Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AT 877

Known as: AT-877, AT877 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
BACKGROUND We have previously demonstrated that long-term inhibition of Rho-kinase ameliorates pulmonary arterial hypertension… Expand
Is this relevant?
Review
2005
Review
2005
BACKGROUND Secondary ischaemia is a frequent cause of poor outcome in patients with subarachnoid haemorrhage (SAH). Its… Expand
Is this relevant?
2001
2001
Fasudil hydrochloride (AT877, hexahydro-1-(5-isoquinolinesulfonyl)-1H-1,4-diazepine hydrochloride, identical to HA1077) inhibits… Expand
Is this relevant?
Review
2001
Review
2001
Fasudil HCl (HA1077, AT877, Eril) was first introduced as a unique vasodilator and intracellular calcium antagonist. It dilated… Expand
Is this relevant?
Review
1998
Review
1998
Background and Purpose: It has been reported that nimodipine reduces the frequency of secondary ischemia and improves outcome… Expand
  • figure 1
  • figure 2
Is this relevant?
1994
1994
Background and Purpose The efficacy of pretreatment with the recently developed intracellular calcium antagonist AT877 against… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
1993
1993
We investigated the effects of AT-877, a Ca2+ antagonist, on rat middle-cerebral artery occlusion. All rats had 6-h ischemia, and… Expand
Is this relevant?
Highly Cited
1992
Highly Cited
1992
With the cooperation of 60 neurosurgical centers in Japan, a prospective randomized placebo-controlled double-blind trial of a… Expand
  • table 2
  • table 1
  • table 3
  • table 4
  • table 5
Is this relevant?
1990
1990
SummaryThe initial dose-escalating clinical trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Review
1990